Patents by Inventor David B. Rozema

David B. Rozema has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formation of polyampholytes in the presence of a polyion
    Patent number: 7470539
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: December 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, Vladimir Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jason Klein, So Wong
  • Endosomolytic Poly(Acrylate) Polymers
    Publication number: 20080287630
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Endosomolytic Poly(Vinyl Ether) Polymers
    Publication number: 20080287628
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers
    Publication number: 20080281044
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 13, 2008
    Inventors: Sean D. Monahan, Lori Higgs, Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Reversibly Masked Polymers
    Publication number: 20080281041
    Abstract: The present invention is directed to reversibly inactivation of membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 13, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom
  • Compounds and Methods for Reversible Modification of Biologically Active Molecules
    Publication number: 20080281074
    Abstract: The present invention is directed compounds for reversibly modification of biologically active molecules. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 13, 2008
    Inventor: David B. Rozema
  • Endosomolytic Poly-Beta-Aminoester Polymers
    Publication number: 20080269450
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: October 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Andrei Blokhin, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Reversible modification of amine-containing compounds
    Patent number: 7442764
    Abstract: An process for the reversible modification of an amine-containing compound is described. Modification of the compound can be used to facilitate delivery of molecules to cells in vitro and in vivo or to alter interactions or activities the compounds. The described modifiers can also be utilized as cross-linkers.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 28, 2008
    Assignee: Mirns Bio Corporation
    Inventors: David B. Rozema, Darren Wakefield, Jon A. Wolff, Kirk Ekena, James E. Hagstrom
  • COMPOSITION FOR IN VIVO DELIVERY
    Publication number: 20080200661
    Abstract: The present invention relates to the delivery of desired compounds (e.g., nucleic acids) into cells using releasable delivery systems which include complexing nucleic acids and delivery ligands.
    Type: Application
    Filed: June 1, 2007
    Publication date: August 21, 2008
    Inventor: David B. Rozema
  • Polyconjugates for In Vivo Delivery of Polynucleotides
    Publication number: 20080152661
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 26, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jason Klein, So Wong, Jon A. Wolff, David L. Lewis, James E. Hagstrom, Andrei Blokhin, Vladimir Trubetskoy, Hans Herweijer
  • Labile Linkage for Compound Delivery to a Cell
    Publication number: 20080132689
    Abstract: Described are ortho carboxy phenol derived acetals and compositions containing ortho carboxy phenol derived acetals which are useful for delivering biologically active compounds to cells. The acetals can be used to reversibly link up to three different molecules and have rapid hydrolysis kinetics in conditions which are present in a cell as well as in vivo. Cleavage of the acetal enhances delivery of the biologically active compound.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 5, 2008
    Inventors: David B. Rozema, Darren Wakefield
  • Labile linkage for compound delivery to a cell
    Patent number: 7348453
    Abstract: Described are ortho carboxy phenol derived acetals and compositions containing ortho carboxy phenol derived acetals which are useful for delivering biologically active compounds to cells. The acetals can be used to reversibly link up to three different molecules and have rapid hydrolysis kinetics in conditions which are present in a cell as well as in vivo. Cleavage of the acetal enhances delivery of the biologically active compound.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: March 25, 2008
    Assignee: Mirus Bio Corporation
    Inventors: David B. Rozema, Darren Wakefield
  • Compositions and methods for drug delivery using pH sensitive molecules
    Patent number: 7208314
    Abstract: A system relating to the delivery of desired compounds (e.g., drugs and nucleic acids) into cells using pH-sensitive delivery systems. The system provides compositions and methods for the delivery and release of a compound to a cell.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: April 24, 2007
    Assignee: Mirus Bio Corporation
    Inventors: Sean D. Monahan, Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker, David B. Rozema
  • Intravascular delivery of non-viral nucleic acid
    Patent number: 7148205
    Abstract: Disclosed is a process for transfecting genetic material into a mammalian cell to alter endogenous properties of the cell. The process comprises designing a polynucleotide for transfection. Then the polynucleotide is inserted into a mammalian vessel such as a tail vein or artery. Prior to insertion, subsequent to insertion, or concurrent with insertion the permeability of the vessel is increased thereby the genetic material is delivered to the parenchymal cell altering endogenous properties of the cell.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: December 12, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Sean D. Monahan, Jon A. Wolff, Paul M. Slattum, James E. Hagstrom, Vladimir G. Budker, David B. Rozema
  • Compositions and methods for drug delivery using pH sensitive molecules
    Patent number: 7138382
    Abstract: A system relating to the delivery of desired compounds (e.g., drugs and nucleic acids) into cells using pH-sensitive delivery systems. The system provides compositions and methods for the delivery and release of a compound to a cell.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: November 21, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, James E. Hagstrom, David B. Rozema, Sean D. Monahan, Vladimir G. Budker
  • Polyampholytes for delivering polyions to a cell
    Patent number: 7098030
    Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: August 29, 2006
    Assignee: Mirus Bio Corporation
    Inventors: David B. Rozema, Vladimir G. Budker, James E. Hagstrom, Vladimir Trubetskoy, Jon A. Wolff, Sean D. Monahan, Paul M. Slattum
  • Compositions and methods for drug delivery using pH sensitive molecules
    Patent number: 7098032
    Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: August 29, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Vladimir S. Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jon A. Wolff, David B. Rozema, Sean D. Monahan
  • Formation of polyampholytes in the presence of a polyion
    Patent number: 7094605
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: August 22, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, Vladimir Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jason Klein, So Wong
  • Compound containing a labile disulfide bond
    Patent number: 7087770
    Abstract: A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: August 8, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, Sean D. Monahan, Vladimir G. Budker, Paul M. Slattum, David B. Rozema
  • pH-titratable polyampholytes for delivering polyions to a cell
    Patent number: 7033607
    Abstract: A polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 25, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Vladimir S. Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jon A. Wolff, David B. Rozema, Sean D. Monahan